JP7654548B2 - 抗ｋｌｒｇ１抗体 - Google Patents

抗ｋｌｒｇ１抗体 Download PDF

Info

Publication number
JP7654548B2
JP7654548B2 JP2021539334A JP2021539334A JP7654548B2 JP 7654548 B2 JP7654548 B2 JP 7654548B2 JP 2021539334 A JP2021539334 A JP 2021539334A JP 2021539334 A JP2021539334 A JP 2021539334A JP 7654548 B2 JP7654548 B2 JP 7654548B2
Authority
JP
Japan
Prior art keywords
antibody
klrg1
seq
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539334A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020060781A5 (https=
JP2022501065A5 (https=
JP2022501065A (ja
Inventor
ヴイ． ガラ ステファノ
エヴァン トンプソン ケニス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2022501065A publication Critical patent/JP2022501065A/ja
Publication of JPWO2020060781A5 publication Critical patent/JPWO2020060781A5/ja
Publication of JP2022501065A5 publication Critical patent/JP2022501065A5/ja
Priority to JP2024127876A priority Critical patent/JP2024156878A/ja
Application granted granted Critical
Publication of JP7654548B2 publication Critical patent/JP7654548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021539334A 2018-09-17 2019-09-06 抗ｋｌｒｇ１抗体 Active JP7654548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024127876A JP2024156878A (ja) 2018-09-17 2024-08-02 抗ｋｌｒｇ１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
US62/732,329 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024127876A Division JP2024156878A (ja) 2018-09-17 2024-08-02 抗ｋｌｒｇ１抗体

Publications (4)

Publication Number Publication Date
JP2022501065A JP2022501065A (ja) 2022-01-06
JPWO2020060781A5 JPWO2020060781A5 (https=) 2022-09-14
JP2022501065A5 JP2022501065A5 (https=) 2022-09-14
JP7654548B2 true JP7654548B2 (ja) 2025-04-01

Family

ID=69887899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539334A Active JP7654548B2 (ja) 2018-09-17 2019-09-06 抗ｋｌｒｇ１抗体
JP2024127876A Pending JP2024156878A (ja) 2018-09-17 2024-08-02 抗ｋｌｒｇ１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024127876A Pending JP2024156878A (ja) 2018-09-17 2024-08-02 抗ｋｌｒｇ１抗体

Country Status (13)

Country Link
US (1) US12365735B2 (https=)
EP (1) EP3852779A4 (https=)
JP (2) JP7654548B2 (https=)
KR (1) KR102934267B1 (https=)
CN (2) CN119638835A (https=)
AU (1) AU2019344524A1 (https=)
BR (1) BR112021004553A2 (https=)
CA (1) CA3113069A1 (https=)
EA (1) EA202190647A1 (https=)
IL (2) IL281594B2 (https=)
MX (2) MX2021003119A (https=)
SG (1) SG11202102114UA (https=)
WO (1) WO2020060781A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020060781A1 (en) 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
AU2022246164A1 (en) * 2021-03-26 2023-09-28 The Brigham And Women’S Hospital, Inc. Anti-klrg1 antibodies
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
WO2017210523A1 (en) 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
WO2018053264A2 (en) 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
WO2006076594A2 (en) 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
AU2011295902B2 (en) 2010-09-02 2014-12-04 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
WO2012145746A1 (en) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
WO2012176765A1 (ja) 2011-06-24 2012-12-27 株式会社ペルセウスプロテオミクス 抗ヒトｐ－カドへリン（ｃｄｈ３）遺伝子組み換え抗体
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2016009487A1 (ja) 2014-07-14 2016-01-21 三菱電機株式会社 空気調和装置
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
WO2017060144A1 (en) 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
US20180371088A1 (en) 2017-06-22 2018-12-27 Development Center For Biotechnology TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
WO2020060781A1 (en) 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
EP3952999A4 (en) 2019-04-09 2023-01-25 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
AU2022246164A1 (en) 2021-03-26 2023-09-28 The Brigham And Women’S Hospital, Inc. Anti-klrg1 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
WO2017210523A1 (en) 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy
WO2018053264A2 (en) 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Klrg1 depletion therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AGE，2009年，Vol.31，p.285-291

Also Published As

Publication number Publication date
IL323170A (en) 2025-11-01
MX2021003119A (es) 2021-05-14
AU2019344524A1 (en) 2021-03-25
WO2020060781A1 (en) 2020-03-26
CN112752580A (zh) 2021-05-04
KR20210060477A (ko) 2021-05-26
IL281594A (en) 2021-05-31
MX2025008993A (es) 2025-09-02
JP2024156878A (ja) 2024-11-06
EP3852779A1 (en) 2021-07-28
CA3113069A1 (en) 2020-03-26
JP2022501065A (ja) 2022-01-06
IL281594B2 (en) 2026-02-01
EA202190647A1 (ru) 2021-09-09
EP3852779A4 (en) 2022-06-08
US12365735B2 (en) 2025-07-22
US20210347899A1 (en) 2021-11-11
BR112021004553A2 (pt) 2021-06-08
SG11202102114UA (en) 2021-04-29
IL281594B1 (en) 2025-10-01
CN112752580B (zh) 2024-12-13
KR102934267B1 (ko) 2026-03-05
CN119638835A (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
JP7654548B2 (ja) 抗ｋｌｒｇ１抗体
AU2003288675B2 (en) Antibodies against PD-1 and uses therefor
JP7368453B2 (ja) Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
KR20200061320A (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
TW202132347A (zh) 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
BR112020015736A2 (pt) Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo
EP1999153A1 (en) Agonist antibodies against tshr
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
CA3255478A1 (en) Anti-tigit-anti-pvrig bispecific antibody, pharmaceutical composition thereof and use thereof
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
EA049153B1 (ru) Антитела к klrg1
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK1083510B (en) Antibodies against pd-1 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220906

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240814

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250319

R150 Certificate of patent or registration of utility model

Ref document number: 7654548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150